



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31/12/2013

PART - I

Rs. in lakhs

| Sl. No. | PARTICULARS | Quarter ended | | | Nine Months ended | | Previous year ended |
|--------------|---|------------------|------------------|-----------------|-------------------|------------------|---------------------|
| | | 31/12/2013 | 30/09/2013 | 31/12/2012 | 31/12/2013 | 31/12/2012 | 31/03/2013 |
| | | Un-audited | Un-audited | Un-audited | Un-audited | Un-audited | Audited |
| 1 | Income from operations | | | | | | |
| | (a) Net sales/income from operations (Net of excise duty) | 11,942.71 | 15,141.23 | 6,239.48 | 37,950.90 | 18,318.10 | 25,788.46 |
| | (b) Other operating income | - | - | - | - | - | - |
| | Total income from operations (net) (a)+(b) | 11,942.71 | 15,141.23 | 6,239.48 | 37,950.90 | 18,318.10 | 25,788.46 |
| 2 | Expenses | | | | | | |
| | a) Cost of materials consumed | 3,576.20 | 4,200.48 | 2,364.64 | 11,151.23 | 6,192.93 | 8,827.40 |
| | b) Purchases of stock-in-trade | - | - | - | - | - | - |
| | c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (1,024.28) | (727.64) | (773.81) | (1,737.23) | (744.88) | (559.63) |
| | d) Employee benefits expense | 893.97 | 759.79 | 768.53 | 2,433.59 | 1,983.08 | 2,537.70 |
| | e) Depreciation and amortisation expense | 224.83 | 221.92 | 219.01 | 656.23 | 572.29 | 786.72 |
| | f) Other expenses - Manufacturing Expenses | 1,340.82 | 1,288.32 | 1,014.79 | 3,788.65 | 2,757.05 | 3,904.81 |
| | - R & D Expenses | 973.08 | 1,789.79 | 929.72 | 3,556.74 | 2,487.20 | 3,469.32 |
| | - Others | 694.40 | 689.27 | 448.96 | 1,824.99 | 1,683.38 | 2,290.30 |
| | Total expenses | 6,679.02 | 8,221.93 | 4,971.84 | 21,674.20 | 14,931.05 | 21,256.62 |
| 3 | Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2) | 5,263.69 | 6,919.30 | 1,267.64 | 16,276.70 | 3,387.05 | 4,531.84 |
| 4 | Other Income | 84.96 | 11.41 | 36.84 | 411.90 | 50.05 | 104.34 |
| 5 | Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4) | 5,348.65 | 6,930.71 | 1,304.48 | 16,688.60 | 3,437.10 | 4,636.18 |
| 6 | Finance costs | 221.43 | 341.28 | 468.53 | 881.77 | 1,080.20 | 1,350.94 |
| 7 | Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6) | 5,127.22 | 6,589.43 | 835.95 | 15,806.83 | 2,356.90 | 3,285.24 |
| 8 | Exceptional Items | - | - | - | - | - | - |
| 9 | Profit/Loss from Ordinary Activities before tax (7 + 8) | 5,127.22 | 6,589.43 | 835.95 | 15,806.83 | 2,356.90 | 3,285.24 |
| 10 | Tax Expenses | 1,483.90 | 2,034.75 | 60.27 | 4,631.64 | 135.99 | 201.29 |
| 11 | Net Profit/ (Loss) from Ordinary Activities after tax (9-10) | 3,643.32 | 4,554.68 | 775.68 | 11,175.19 | 2,220.91 | 3,083.95 |
| 12 | Extraordinary Items (net of tax expense Rs____) | - | - | - | - | - | - |
| 13 | Net Profit / (Loss) for the period (11 + 12) | 3,643.32 | 4,554.68 | 775.68 | 11,175.19 | 2,220.91 | 3,083.95 |
| 14 | Share of profit / (loss) of associates | - | - | - | - | - | - |
| 15 | Minority interest | - | - | - | - | - | - |
| 16 | Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) | 3,643.32 | 4,554.68 | 775.68 | 11,175.19 | 2,220.91 | 3,083.95 |
| 17 | Paid-up equity share capital (Face Value of Rs. 1/- each) | 1,168.29 | 1,168.29 | 1,167.32 | 1,168.29 | 1,167.32 | 1,168.29 |
| 18 | Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year | - | - | - | - | - | 14,277.70 |
| 19.i | Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised): | | | | | | |
| | a) Basic | 3.12 | 3.90 | 0.66 | 9.57 | 1.90 | 2.64 |
| | b) Diluted | 3.12 | 3.90 | 0.66 | 9.57 | 1.90 | 2.64 |
| 19.ii | Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised): | | | | | | |
| | a) Basic | 3.12 | 3.90 | 0.66 | 9.57 | 1.90 | 2.64 |
| | b) Diluted | 3.12 | 3.90 | 0.66 | 9.57 | 1.90 | 2.64 |

| PART - II | | 31/12/2013 | 30/09/2013 | 31/12/2012 | 31/12/2013 | 31/12/2012 | 31/03/2013 |
|-----------|--|-----------------------------|------------|------------|------------|------------|------------|
| A | PARTICULARS OF SHAREHOLDING | Un-audited | Un-audited | Un-audited | Un-audited | Un-audited | Audited |
| 1 | Public share holdings | | | | | | |
| | a. Number of shares | 41,171,212 | 41,171,212 | 42,679,160 | 41,171,212 | 42,679,160 | 41,993,960 |
| | b. Percentage of share holding | 35.24% | 35.24% | 36.56% | 35.24% | 36.56% | 35.94% |
| 2 | Promoters and promoter group Shareholding | | | | | | |
| | a) Pledged / Encumbered | | | | | | |
| | - Number of shares | NIL | NIL | NIL | NIL | NIL | NIL |
| | - Percentage of shares (as a % of the total shareholding of promoter and promoter group) | NIL | NIL | NIL | NIL | NIL | NIL |
| | - Percentage of shares (as a % of the total share capital of the company) | NIL | NIL | NIL | NIL | NIL | NIL |
| | b) Non-Encumbered | | | | | | |
| | - Number of shares | 75,657,576 | 75,657,576 | 74,052,828 | 75,657,576 | 74,052,828 | 74,834,828 |
| | - Percentage of shares (as a % of the total shareholding of promoter and promoter group) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| | - Percentage of shares (as a % of the total share capital of the company) | 64.76% | 64.76% | 63.44% | 64.76% | 63.44% | 64.06% |
| | Particulars | 3 months ended (31/12/2013) | | | | | |
| B | INVESTOR COMPLAINTS | | | | | | |
| | Pending at the beginning of the quarter | 0 | | | | | |
| | Received during the quarter | 25 | | | | | |
| | Disposed of during the quarter | 25 | | | | | |
| | Remaining unresolved at the end of the quarter | 0 | | | | | |

| SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED | | | | | | | Rs. in lakhs |
|--|--|------------------|------------------|-------------------|------------------|------------------|------------------|
| PARTICULARS | Quarter ended | | | Nine Months ended | | Year ended | |
| | 31/12/2013 | 30/09/2013 | 31/12/2012 | 31/12/2013 | 31/12/2012 | 31/03/2013 | |
| | Un-audited | Un-audited | Un-audited | Un-audited | Un-audited | Audited | |
| 1 | SEGMENT REVENUE | | | | | | |
| | a) Manufacturing (CRAMS) | 11,229.62 | 14,742.29 | 5,402.01 | 36,660.43 | 16,276.13 | 24,456.23 |
| | b) Services (DDDSS) | 713.08 | 398.95 | 837.46 | 1,290.46 | 2,041.96 | 1,332.24 |
| | c) Research & Development | - | - | - | - | - | - |
| | Net sales/income from operations | 11,942.70 | 15,141.24 | 6,239.47 | 37,950.89 | 18,318.09 | 25,788.47 |
| 2 | SEGMENT RESULTS (Profit/(Loss) before tax and interest) | | | | | | |
| | a) Manufacturing (CRAMS) | 6,327.79 | 8,859.93 | 1,904.71 | 20,367.42 | 5,816.12 | 9,176.71 |
| | b) Services (DDDSS) | 459.14 | 213.02 | 618.02 | 687.99 | 1,255.51 | 370.00 |
| | c) Research & Development | (973.08) | (1,789.79) | (929.72) | (3,556.74) | (2,487.20) | (3,469.32) |
| | TOTAL | 5,813.85 | 7,283.16 | 1,593.01 | 17,498.67 | 4,584.43 | 6,077.39 |
| | Less: (i) Interest | 117.92 | 194.13 | 441.82 | 529.48 | 1,001.37 | 1,174.34 |
| | (ii) Other Un-allocable expenses net off | 568.71 | 499.60 | 315.24 | 1,162.36 | 1,226.56 | 1,617.81 |
| | (iii) un-allocable Income | - | - | - | - | - | - |
| | Profit Before Tax | 5,127.22 | 6,589.43 | 835.95 | 15,806.83 | 2,356.50 | 3,285.24 |
| 3 | CAPITAL EMPLOYED (Segment Assets - Segment Liabilities) | | | | | | |
| | a) Manufacturing (CRAMS) | 21,824.86 | 23,091.94 | 13,053.17 | 21,824.86 | 13,053.17 | 13,212.39 |
| | b) Services (DDDSS) | 3,367.54 | 3,264.03 | 3,035.70 | 3,367.54 | 3,035.70 | 3,093.23 |
| | c) Research & Development | 2,136.36 | 2,259.21 | 2,157.59 | 2,136.36 | 2,157.59 | 2,503.65 |
| | d) Net assets which are not segmented and used commonly | (707.60) | (5,637.34) | 4,237.93 | (707.60) | 4,237.93 | (3,363.29) |
| | TOTAL | 26,621.16 | 22,977.84 | 22,484.39 | 26,621.16 | 22,484.39 | 15,445.98 |

Notes:

- The above un-audited results were approved and taken on record at the Board of Directors' meeting held on 4th February, 2014.
- Previous years figures have been regrouped/reclassified whenever necessary.
- Suven Nishta Pharma Pvt Ltd., the 100% subsidiary, has been merged w.e.f. 1st January, 2012 and accordingly the results have been prepared. Hence the current quarter figures are not comparable with the previous corresponding quarter figures.
- The limited review for 3rd quarter has been done by the Statutory Auditors.

For SUVEN LIFE SCIENCES LTD

Place : Hyderabad
Date : 04th February, 2014

VENKAT JASTI
Chairman & CEO

We Deliver